The recurrence rate of stage IA ovarian cancer is not zero. For patients with stage IA ovarian cancer, if there are no high-risk factors, the 5-year survival rate of patients through surgical resection can reach more than 95%, so the cure rate is very high, and there is no need to carry out adjuvant chemotherapy after surgery, as long as the regular rechecking can be done. However, if the DNA ploidy of the tumor cells is polyploid, the prognosis is poorer and the tumor may recur and metastasize. Therefore, if the tumor of stage IA ovarian cancer patient is hypo-differentiated, that is, polyploid, or the pathological type is clear cell carcinoma, carcinosarcoma, etc. chemotherapy can be considered. Patients can benefit from postoperative adjuvant chemotherapy, which is currently mainly combination chemotherapy with paclitaxel combined with carboplatin, requiring 3-6 cycles of chemotherapy.